Literature DB >> 6651248

Cerebral vasospasm after subarachnoid hemorrhage: an update.

R C Heros, N T Zervas, V Varsos.   

Abstract

Symptomatic vasospasm, or delayed cerebral ischemia associated with arteriographic evidence of arterial constriction, is currently the most important cause of morbidity after acute subarachnoid hemorrhage. The development of vasospasm is directly correlated with the presence of thick blood clots in the basal subarachnoid cisterns, which can be detected by an early computed tomographic scan. Symptomatic vasospasm usually develops between 4 and 12 days after subarachnoid hemorrhage. The onset is gradual, occurring over hours or days. There is typically a gradual deterioration of the level of consciousness, accompanied by focal neurological deficits that are determined by the arterial territories involved. Hyponatremia frequently occurs and may exacerbate the symptoms. The patients are usually volume depleted, and therefore many authorities now treat them with replenishment and expansion of their intravascular volume with colloid and blood. Volume expansion, together with elevation of the systemic blood pressure and reduction of the intracranial pressure when elevated, constitute the only currently available effective therapy for symptomatic vasospasm. The cause of vasospasm remains obscure. Mechanisms of smooth muscle cell contraction and relaxation and experimental efforts to elucidate the nature of vasospasm are reviewed.

Entities:  

Mesh:

Year:  1983        PMID: 6651248     DOI: 10.1002/ana.410140602

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  55 in total

1.  Endovascular management of cerebral aneurysms.

Authors:  A Berenstein
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

2.  Stellate ganglion block combined with intra-arterial treatment: a "one-stop shop" for cerebral vasospasm after aneurysmal subarachnoid hemorrhage-a pilot study.

Authors:  Marco Pileggi; Pascal J Mosimann; Maurizio Isalberti; Eike Immo Piechowiak; Paolo Merlani; Michael Reinert; Alessandro Cianfoni
Journal:  Neuroradiology       Date:  2021-03-16       Impact factor: 2.804

Review 3.  Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage.

Authors:  James K Liu; William T Couldwell
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Unsecured intracranial aneurysms and induced hypertension in cerebral vasospasm: is induced hypertension safe?

Authors:  Johannes Platz; Erdem Güresir; Hartmut Vatter; Joachim Berkefeld; Volker Seifert; Andreas Raabe; Jürgen Beck
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

5.  Nicardipine HCl: clinical experience in patients undergoing anaesthesia for intracranial aneurysm clipping.

Authors:  D S Warner; M D Sokoll; M Maktabi; J C Godersky; H P Adams
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

6.  Ultrastructural changes induced by experimental subarachnoid haemorrhage and 6-hydroxydopamine in cat cerebral arteries.

Authors:  F Rivilla; J Marín; C F Sánchez-Ferrer; M Salaices; P G Ramos
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 7.  Critical care management of subarachnoid hemorrhage.

Authors:  Joshua M Levine
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

8.  Outcome of patients with aneurysmal and presumed aneurysmal bleeding. A hospital study based on 100 consecutive cases in a neurological clinic.

Authors:  H Schütz; P Krack; B Buchinger; R H Bödeker; A Laun; W Dorndorf; A Agnoli
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

Review 9.  Clinical translation of nitrite therapy for cardiovascular diseases.

Authors:  John W Calvert; David J Lefer
Journal:  Nitric Oxide       Date:  2009-11-10       Impact factor: 4.427

10.  Evaluation of cerebral vasospasm in patients with subarachnoid hemorrhage using single photon emission computed tomography.

Authors:  S Naderi; M A Ozgüven; H Bayhan; H Gökalp; A Erdoğan; N Egemen
Journal:  Neurosurg Rev       Date:  1994       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.